The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study

Nephrology

Volumn 20, Issue 3, 2015, Pages 140-147

  Roberts, Matthew A ^a   Pilmore, Helen L ^b   Ierino, Francesco L ^c,d   Badve, Sunil V ^e,f   Cass, Alan ^g   Garg, Amit X ^h   Hawley, Carmel M ^e,f   Isbel, Nicole M ^f   Krum, Henry ^a   Pascoe, Elaine M ^e   Tonkin, Andrew M ^a   Vergara, Liza A ^e   Perkovic, Vlado ⁱ  

^a MONASH UNIVERSITY   (Australia)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c Austin Health   (New Zealand)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f PRINCESS ALEXANDRA HOSPITAL   (Australia)

^g MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^h UNIVERSITY OF WESTERN ONTARIO   (Canada)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

Author keywords

beta blocking agent; feasibility study; haemodialysis; peritoneal dialysis; randomized controlled trial

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; PLACEBO; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; AUSTRALIA AND NEW ZEALAND; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEASIBILITY STUDY; FEMALE; HEMODIALYSIS; HUMAN; HYPOTENSION; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; ADVERSE EFFECTS; AUSTRALIA; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPLICATION; KIDNEY FAILURE, CHRONIC; MEDICATION COMPLIANCE; METHODOLOGY; MIDDLE AGED; NEW ZEALAND; PATIENT SELECTION; RENAL REPLACEMENT THERAPY; SAMPLE SIZE; TIME; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AUSTRALIA; CARBAZOLES; CARDIOVASCULAR DISEASES; CLINICAL PROTOCOLS; DOUBLE-BLIND METHOD; FEASIBILITY STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEW ZEALAND; PATIENT SELECTION; PERITONEAL DIALYSIS; PROPANOLAMINES; RENAL DIALYSIS; RESEARCH DESIGN; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923374430     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/nep.12362     Document Type: Article

References (29)

1. Freemantle N, Cleland J, Young P, Mason J, Harrison J,. Beta-blockade after myocardial infarction: Systematic review and meta regression analysis. BMJ 1999; 318: 1730-1737.
2. Shibata MC, Flather MD, Wang D,. Systematic review of the impact of beta-blockers on mortality and hospital admissions in heart failure. Eur. J. Heart Fail. 2001; 3: 351-357.
3. McMurray J, Køber L, Robertson M, et al. Antiarrhythmic effect of carvedilol after acute myocardial infarction: Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J. Am. Coll. Cardiol. 2005; 45: 525-530.
4. Adamson PB, Gilbert EM,. Reducing the risk of sudden death in heart failure with beta-blockers. J. Card. Fail. 2006; 12: 734-746.
5. Foley RN, Parfrey PS, Sarnak MJ,. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998; 32: S112-119.
6. Whalley GA, Marwick TH, Doughty RN, et al. Effect of early initiation of dialysis on cardiac structure and function: Results from the echo substudy of the IDEAL trial. Am. J. Kidney Dis. 2013; 61: 262-270.
7. Converse RL, Jr, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N. Engl. J. Med. 1992; 327: 1912-1918.
8. Badve SV, Roberts MA, Hawley CM, et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease: A systematic review and meta-analysis. J. Am. Coll. Cardiol. 2011; 58: 1152-1161.
9. Cice G, Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J. Am. Coll. Cardiol. 2003; 41: 1438-1444.
10. Agarwal R, Sinha AD, Pappas MK, Abraham TN, Tegegne GG,. Hypertension in hemodialysis patients treated with atenolol or lisinopril: A randomized controlled trial. Nephrol. Dial. Transplant. 2014; 29: 672-681.
11. Wali RK, Iyengar M, Beck GJ, et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: A meta-analysis of randomized trials. Circ. Heart Fail. 2011; 4: 18-26.
12. Bakris GL, Fonseca V, Katholi RE, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: A randomized controlled trial. JAMA 2004; 292: 2227-2236.
13. Bakris GL, Hart P, Ritz E,. Beta-blockers in the management of chronic kidney disease. Kidney Int. 2006; 70: 1905-1913.
14. Dulin B, Abraham WT,. Pharmacology of carvedilol. Am. J. Cardiol. 2004; 93: 3-6.
15. Kojima M, Sato K, Kimura G, Ueda R, Dohi Y,. Carvedilol reduces elevated B-type natriuretic peptide in dialyzed patients without heart failure: Cardioprotective effect of the beta-blocker. J. Cardiovasc. Pharmacol. 2007; 49: 191-196.
16. Roberts MA, Srivastava PM, Macmillan N, et al. B-type natriuretic peptides strongly predict mortality in patients who are treated with long-term dialysis. Clin. J. Am. Soc. Nephrol. 2008; 3: 1057-1065.
17. Gutierrez OM, Tamez H, Bhan I, et al. N-terminal Pro-B-Type natriuretic peptide concentrations in hemodialysis patients: Prognostic value of baseline and follow-up measurements. Clin. Chem. 2008; 54: 1339-1348.
18. Glasziou P, Alexander J, Beller E, Clarke P,. Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Health Qual. Life Outcomes 2007; 5: 21-31.
19. Di Lenarda A, Remme WJ, Charlesworth A, et al. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial). Eur. J. Heart Fail. 2005; 7: 640-649.
20. Roberts MA, Pilmore HL, Tonkin AM, et al. Challenges in blood pressure measurement in patients treated with maintenance hemodialysis. Am. J. Kidney Dis. 2012; 60: 463-472.
21. Agarwal R, Light RP,. Median intradialytic blood pressure can track changes evoked by probing dry-weight. Clin. J. Am. Soc. Nephrol. 2010; 5: 897-904.
22. Hickman PE, Koerbin G, Southcott E, et al. Newer cardiac troponin I assays have similar performance to troponin T in patients with end-stage renal disease. Ann. Clin. Biochem. 2007; 44: 285-289.
23. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: A systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009-1015.
24. Agarwal R, Light RP,. Chronobiology of arterial hypertension in hemodialysis patients: Implications for home blood pressure monitoring. Am. J. Kidney Dis. 2009; 54: 693-701.
25. Roberts MA, Polkinghorne KR, McDonald SP, Ierino FL,. Secular trends in cardiovascular mortality rates of patients receiving dialysis compared with the general population. Am. J. Kidney Dis. 2011; 58: 64-72.
26. Tentori F,. Trends in medication use and clinical outcomes in twelve countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Contrib. Nephrol. 2008; 161: 48-54.
27. Wetmore JB, Mahnken JD, Mukhopadhyay P, et al. Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients. Am. J. Kidney Dis. 2011; 58: 73-83.
28. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: The what, why and how. BMC Med. Res. Methodol. 2010; 10: 1.
29. Lancaster GA, Dodd S, Williamson PR,. Design and analysis of pilot studies: Recommendations for good practice. J. Eval. Clin. Prac. 2004; 10: 307-312.